Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 24, 2021
- Accepted in final form November 23, 2021
- First Published December 17, 2021.
Article Versions
- Previous version (December 17, 2021 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Katarzyna Krzywicka, MD, MPhil*,
- Anita van de Munckhof, MD*,
- Mayte Sánchez van Kammen, MD,
- Mirjam R. Heldner, MD, MSc,
- Katarina Jood, MD, PhD,
- Erik Lindgren, MD,
- Turgut Tatlisumak, MD, PhD,
- Jukka Putaala, MD, PhD,
- Johanna A. Kremer Hovinga, MD,
- Saskia Middeldorp, MD, PhD,
- Marcel M. Levi, MD, PhD,
- Charlotte Cordonnier, MD, PhD,
- Marcel Arnold, MD,
- Aeilko H. Zwinderman, MD, PhD,
- José M. Ferro, MD, PhD,
- Jonathan M. Coutinho, MD, PhD† and
- Diana Aguiar de Sousa, MD, PhD†
- Katarzyna Krzywicka, MD, MPhil*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anita van de Munckhof, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mayte Sánchez van Kammen, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Mirjam R. Heldner, MD, MSc,
Scientific advisory board honoraria from Amgen, not directly related to this manuscript.
NONE
Travel support from Bayer, not directly related to this manuscript.
Being a member of the ESO Board of Directors and of the ESO Education Committee, not directly related to this manuscript.
NONE
NONE
NONE
NONE
NONE
Grants from the Bangerter Foundation and the Swiss Heart Foundation, not directly related to this manuscript.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katarina Jood, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
the Swedish State under the ALF agreement (ALFGBG-720211), and Region Västra Götaland (VGFOUREG-662151)
NONE
Research grants from (1) The John and Brit Wennerströms Foundation, (2) The Per-Olof Ahl Foundation, Peter Erikssons Foundation, and (3) The Rune and Ulla Amlöv Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Erik Lindgren, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research grants from (1) The Swedish Neurological Society, (2) Elsa and Gustav Lindh's Foundation, (3) P-o Ahl's Foundation, (4) Rune and Ulla Amlöv's Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Turgut Tatlisumak, MD, PhD,
Bayer, Bristol Myers Squibb, Portola Pharm
NONE
Congress traveling and accommodation costs (none commercial): European Stroke Organisation University of Donau (Austria) 2nd Stroke Academy Meeting, Istanbul, Turkey
Current Vascular Pharmacology, 2002- Stroke Research and Treatment, 2009- Frontiers in Stroke, 2010- European Stroke Journal, 2016- Therapeutic Advances in Neurological Disorders, 2017- No compensation was received for any of the above editorial duties
1. New Therapeutic Uses (method to prevent brain edema and reperfusion injury), PCT/FI2004/000070. Inventors: Lindsberg PJ, Karjalainen-Lindsberg M-L, Tatlisumak T, Strbian D. Applicant: Licentia Oy. Application date: February 13, 2003. Publication 7/2003, Application number: 20030224. 2. Thrombolytic compositions (method to prevent postthrombolytic hemorrhage formation), PCT/FI2004/000071. Inventors: Lindsberg PJ, Karjalainen- Lindsberg M-L, Tatlisumak T, Strbian D, Kovanen P. Applicant: Licentia Oy. Application date: February 13, 2003. Publication: 3/2003. Application number: 20030225.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
University of Gothenburg Research Funds, PI Sahlgrenska University Hospital Research Funds, PI European Union
NONE
Wennerströms Foundation, PI
NONE
NONE
NONE
NONE
NONE
NONE
- Jukka Putaala, MD, PhD,
(1) Advisory Board: Boehringer-Ingelheim (2) Advisory Board: Bayer (3) Advisory Board: BMS-Pfizer (4) Advisory Board: Portola (5) Advisory Board: Herantis Pharma
NONE
(1) Speaker honoraria: Boehringer-Ingelheim (2) Speaker honoraria: Bayer (3) Speaker honoraria: BMS-Pfizer (4) Speaker honoraria: Abbott
(1) European Stroke Journal: Member of the Editorial Board (2) Terve Media: Visiting Editor
NONE
NONE
NONE
NONE
NONE
(1) Trial site-PI: Bayer (2) Trial site-PI: Amgen
NONE
(1) Nonrestricted grant from Pfizer
(1) Helsinki-Uusimaa Hospital District, PI (2) Academy of Finland, PI
NONE
(1) Finnish Foundation for Cardiovascular Research Stock/Stock Options, Medical Equipment & Materials: (1) Stock ownership: Vital Signum
NONE
NONE
NONE
NONE
NONE
NONE
- Johanna A. Kremer Hovinga, MD,
1) Takeda 2) Ablynx/Sanofi
NONE
NONE
1) Haemostaseologie, Advisory/Editorial Board, 9y 2) Thrombosis Journal, Editorial Board, 9y 3) Research and Practice in Thrombosis and Haemostasis, Editorial Board, 6y 4) HemaSphere, Editorial Board, 3y 5) Haematologica, Editorial Board, 1y
NONE
NONE
NONE
All Honroaria go to my employer, INSEL Gruppe AG (Bern University Hospital) 1) CSL Behring 2) NovoNordisk 3) Roche 4) Federal Bureau of Public Health (FOPH) Switzerland
All Honroaria go to my employer, INSEL Gruppe AG (Bern University Hospital) 1) CSL Behring 2) NovoNordisk 3) Roche
NONE
NONE
1) Unresistrcted research grant from Baxter/Takeda for the International Hereditary Thrombotic Thrombocytopenic Purpura Registry 2) Interprofessional Hemophilia Care at EHCCC Inselspital is supported by grants from Bayer, CSL Behring, NovoNordisk, Octapharma, Sobi, and Roche
Swiss National Science Foundation (Grant 310030-185233); PI; 07/2019  06/2022; topic: ÂThrombotic thrombocytopenic purpura  the role of ADAMTS13 and long-term outcomeÂ
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Saskia Middeldorp, MD, PhD,
Bayer, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Portola: advisory board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marcel M. Levi, MD, PhD,
NONE
NONE
NONE
J Thrombosis Hemostasis Thrombosis Research Eur J Int Med Seminars Thrombosis Hemostasis ALL UNCOMPENSATED
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Charlotte Cordonnier, MD, PhD,
BMS, steering committee (ongoing) Biogen, steering committee (ongoing) Astra-Zeneca, advisory board (on secondary prevention after minor strokes)- terminated University of Glasgow, DSMB (unpaid-ongoing)
NONE
NONE
Stroke, Associate editor, 2020-ongoing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
French ministry of health, PHRC A3ICH, PI, 2016-ongoing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marcel Arnold, MD,
None
NONE
None
J Thrombosis HemostasisThrombosis ResearchEur J Int MedSeminars Thrombosis HemostasisALL UNCOMPENSATED
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Aeilko H. Zwinderman, MD, PhD,
(1) commerical: DSMB membership of a study organized by Torrent Pharmaceutical (India) on a a new compound for cardiovascular diseases
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- José M. Ferro, MD, PhD,
Boehringer Ingelheim
NONE
Boehringer Ingelheim
NONE
NONE
NONE
NONE
Boehringer Ingelheim, Bayer
Boehringer Ingelheim
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan M. Coutinho, MD, PhD† and
(1) Boehringer Ingelheim, Bayer, Portola and Medtronic. All fees were paid to my employer, Amsterdam University Medical Centers, and were used to fund academic research.
NONE
NONE
(1) Stroke, Editorial Board Member, 2017-now (2) Journal of Neurology, Editorial Board member 2021-now (3) Frontiers in Neurology, associate Editor, 2020-now (4) BMC Neurology, Associate Editor, 2018-2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) ZonMw, grant number 10430072110005, 2021
(1) Dr. C.J. Vaillant Fonds
(1) Dutch Heart Foundation (2) Dutch Thrombosis Foundation (3) Health Holland (4) EU funding (Eurostars)
NONE
NONE
NONE
NONE
NONE
NONE
- Diana Aguiar de Sousa, MD, PhD†
(1) Sponsor: Dr. Thalia Field; Funders: Canadian Institutes of Health Research, Canadian Stroke Consortium, and Heart and Stroke Foundation of Canada; Study of rivaroxaban for CeREbral venous Thrombosis (SECRET trial); Data Safety Monitoring Board member. (2) Advisory Board participation for Astrazeneca
NONE
Boehringer Ingelheim, nonfinancial support outside of the submitted work (travel expenses)
Stroke (AHA/ASA journals), member of the editorial board, 2019 Stroke (AHA/ASA journals), assistant editor, 2019 European Stroke Journal, member of the editorial board, since 2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Fundação para Ciência e Tecnologia, SFRH/SINTD/92677/2013, PhD student, 2014-2018
NONE
(1) Fundação AstraZeneca, 11º Bolsa de Investigação Fundação AstraZeneca - Faculdade de Medicina Universidade de Lisboa (2) Fundação Amélia de Mello, D. Manuel de Mello grant
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neurology (K.K., A.v.d.M., M.S.v.K., J.M.C.) and Vascular Medicine (M.M.L.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; Departments of Neurology (M.R.H., M.A.) and Hematology (J.A.K.H.), Inselspital, Bern University Hospital, University of Bern; Department of Neurology (K.J., E.L., T.T.), Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J., E.L., T.T.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden; Department of Neurology (J.P.), Helsinki University Hospital and University of Helsinki, Finland; Department of Internal Medicine (S.M.) and Radboud Institute of Health Sciences (S.M.), Radboud University Medical Center, Nijmegen, the Netherlands; National Institute for Health Research University College London Hospitals Biomedical Research Centre (M.M.L.), UK; University of Lille (C.C.), Inserm, CHU Lille, U1172–Lille Neuroscience and Cognition, France; Department of Clinical Epidemiology and Biostatistics (A.H.Z.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; and Department of Neurosciences and Mental Health (J.M.F., D.A.d.S.), Neurology Service, Hospital de Santa Maria/Centro Hospitalar Universitário Lisboa Norte (CHULN), University of Lisbon, Portugal.
- Correspondence
Dr. Aguiar de Sousa dianasousa{at}campus.ul.pt
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.